Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Long-Term Investors Should Skip AMC Stock

By Tezcan Gecgil, InvestorPlace Contributor
AMC stock has certainly had an impressive several months, but a real recovery for AMC is unlikely due to streaming and Covid-19.

Mind Medicine Has More Obstacles Than Opportunities

By Muslim Farooque, InvestorPlace Contributor
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business.

Forget the Optimism, Harley Davidson Is a Flawed Stock

By Steve Booyens, CFA
Optimism in HOG stock doesn't make sense, as the business is suffering from rebranding pressure and inefficient operational processes.

Avoid Unprofitable Clover Health For the Forseeable Future

By Mark R. Hake, CFA
Clover Health will not be profitable anytime soon, so stay away. CLOV stock is not worth more than $7.86 at best, or 4% below today’s price at 3 times forward sales.

7 Stocks to Avoid… Unless You Like Losing Money

By Joel Baglole, InvestorPlace Contributor
Keeping up with market shifts has been difficult, but there are some names that investors should avoid at all costs right now as they are likely to continue falling over the short and medium term.

Opendoor Technologies Is Vulnerable to the Housing Market’s Double-Edged Sword

By Josh Enomoto, InvestorPlace Contributor
While the underlying technology behind OPEN stock is intriguing, the reality is that the housing market may not cooperate.

AMC Entertainment May Have Missed Its Last Chance at Salvation

By Ian Bezek, InvestorPlace Contributor
AMC's bonds are selling off as liquidity concerns mount. This has added an unnecessary roadblock in the AMC turnaround effort.

Carnival Is Caught in a High-Stakes Contest It Might Not Win

By Josh Enomoto, InvestorPlace Contributor
While CCL stock should be moving higher because of the cruise ship industry’s green light, the politics of Covid is rearing its ugly head.

Avoid DiDi Global Stock Like the Plague as China Flexes Its Muscles

By Joel Baglole, InvestorPlace Contributor
No sooner had Chinese ride hailing company DiDi Global held its American IPO on June 30, than the Chinese government in Beijing cracked down on the company, sending its newly listed shares on the New York Stock Exchange plunging nearly 40%. The stock has since recovered somewhat and now trades at $13.08 per share. But with Chinese authorities continuing to punish DiDi Global, should any investor risk taking a position?

Alibaba Stock Is Too Risky as China’s Crackdown Continues

By Larry Ramer, InvestorPlace Contributor
Dictatorships often react very harshly to criticism, so BABA stock is very vulnerable after Jack Ma blasted Beijing last year.

There’s No Good Way to Actually Judge Airbnb’s Value

By Tom Kerr, InvestorPlace Contributor
The concept driving ABNB stock is unproven, and it's too early to really know whether the company will thrive or fail entirely.

Avoid DiDi Global Amid a Government Crackdown

By Chris Lau, InvestorPlace Contributor
DIDI stock is not investable now that Beijing is scrutinizing its customer data practices and troubling investors with uncertainties.

Churchill Capital Corp IV Isn’t Just Overvalued, It’s Caught up in the Meme Stock Spiral

By Larry Ramer, InvestorPlace Contributor
Given the risks facing CCIV stock and its huge valuation -- along with the retreat of the meme names -- the shares are likely to tumble for the foreseeable future.

Orphazyme Stock Is a Dead-End for Investors After FDA Rejection

By Muslim Farooque, InvestorPlace Contributor
ORPH stock has a virtually impossible task ahead of it in picking itself after FDA's rejection of the Danish biopharma's Arimoclomol drug.

Ocugen Stock Is Well Past Its Expiration Date and It Shows

By Joseph Nograles
There won’t be a market for COVAXIN in the US as vaccination rates continue moving up. Without a successful US launch of COVAXIN, OCGN stock doesn’t even warrant the price of a dollar.

Fisker Stock Isn’t Worth Considering Until It Starts Building Actual Cars

By Vandita Jadeja
Fisker has a long way to go before it goes into production and betting on FSR stock is like investing into speculation.

Alibaba Stock Is Too Vulnerable to China to Be the Sure Thing It Once Was

By Wayne Duggan, InvestorPlace Contributor
Alibaba has been the closest thing China has to Amazon. However, China's crackdown on tech companies makes BABA stock a risky investment.

7 Stocks to Sell That Are Simply Too Far Gone to Resuscitate

By Ian Bezek, InvestorPlace Contributor
Traders are making a big play on short squeeze stock and economic recovery names. But these stocks to sell have missed their comeback chance.

Sell ContextLogic Stock As Reddit Traders Move On

By Chris Lau, InvestorPlace Contributor
Stock momentum in WISH faded in recent trading sessions, which suggests a peak and a sharp downtrend from here.
Load More Articles